Arovella Therapeutics Ltd (ASX: ALA) Share Price and News
Price
$0.075
Movement
0.00 (0.0)
as at 16 Jun - Closed (20 mins delayed)
52 Week Range
$0.068 - $0.21
1 Year Return
-44.44%
Arovella Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$88.79 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.18 billion
Earnings per share
-0.006
Dividend per share
N/A
Year To Date Return
-52.94%
Earnings Yield
N/A
Franking
-
Share Price
$0.075
Day Change
0.00 (0.0)
52 Week Range
$0.068 - $0.21
Yesterday's Close
$0.075
Today's Open
–
Days Range
– - –
Volume
0
Avg. Volume (1 month)
1,953,730
Turnover
$0
as at 16 Jun - Closed
Arovella Therapeutics Ltd (ASX: ALA)
Latest News
Share Market News
Suda Pharmaceuticals share price soars 200% on TGA approval
ALA ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About Arovella Therapeutics Ltd
Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. Its activities include pharmaceutical development of drug delivery technology and medical devices and consumables distribution. The company operates through following business segment: Suda; and Malaria Research Company. The Suda segment includes research and development to create new human pharmaceutical products by combining proven drugs with innovated, patented, delivery technologies. The Malaria Research Company segment segment is the pharmaceutical development segment for the treatment of malaria. Arovella Therapeutics was founded on December 21, 1999 and is headquartered in Osborne Park, Australia.
ALA Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Jun 2025 | $0.08 | $-0.01 | -12.05% | 4,804,237 | $0.08 | $0.08 | $0.07 |
| 12 Jun 2025 | $0.08 | $0.00 | 0.00% | 1,897,905 | $0.08 | $0.09 | $0.08 |
| 11 Jun 2025 | $0.08 | $0.00 | 0.00% | 3,889,096 | $0.08 | $0.08 | $0.08 |
| 10 Jun 2025 | $0.08 | $0.00 | 0.00% | 3,695,373 | $0.08 | $0.08 | $0.07 |
| 06 Jun 2025 | $0.08 | $0.00 | 0.00% | 2,819,806 | $0.08 | $0.08 | $0.07 |
| 05 Jun 2025 | $0.08 | $0.00 | 0.00% | 668,883 | $0.08 | $0.08 | $0.08 |
| 04 Jun 2025 | $0.08 | $0.00 | 0.00% | 3,325,449 | $0.08 | $0.08 | $0.08 |
| 03 Jun 2025 | $0.08 | $0.00 | 0.00% | 1,680,333 | $0.08 | $0.08 | $0.08 |
| 02 Jun 2025 | $0.08 | $0.00 | 0.00% | 1,381,283 | $0.08 | $0.08 | $0.07 |
| 30 May 2025 | $0.08 | $0.00 | 0.00% | 1,454,315 | $0.08 | $0.08 | $0.08 |
| 29 May 2025 | $0.08 | $0.00 | 0.00% | 2,795,099 | $0.08 | $0.08 | $0.07 |
| 28 May 2025 | $0.08 | $0.00 | 0.00% | 2,068,831 | $0.07 | $0.08 | $0.07 |
| 27 May 2025 | $0.07 | $0.00 | 0.00% | 2,839,011 | $0.08 | $0.08 | $0.07 |
| 26 May 2025 | $0.07 | $0.00 | 0.00% | 965,932 | $0.08 | $0.08 | $0.07 |
| 23 May 2025 | $0.08 | $0.00 | 0.00% | 1,223,601 | $0.07 | $0.08 | $0.07 |
| 22 May 2025 | $0.07 | $-0.01 | -12.99% | 951,780 | $0.08 | $0.08 | $0.07 |
| 21 May 2025 | $0.08 | $0.00 | 0.00% | 360,774 | $0.08 | $0.08 | $0.08 |
| 20 May 2025 | $0.08 | $0.00 | 0.00% | 616,267 | $0.08 | $0.08 | $0.08 |
| 19 May 2025 | $0.08 | $0.00 | 0.00% | 420,656 | $0.08 | $0.08 | $0.08 |
| 16 May 2025 | $0.08 | $0.00 | 0.00% | 1,215,964 | $0.08 | $0.08 | $0.08 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 26 Nov 2024 | Gary Phillips | Issued | 354,000 | $65,490 |
Director remuneration.
|
| 26 Nov 2024 | Thomas (Tom) Duthy | Issued | 620,000 | $114,700 |
Director remuneration.
|
| 26 Nov 2024 | Michael Baker | Issued | 1,658,483 | $306,819 |
Director remuneration.
|
| 26 Nov 2024 | Debora Barton | Issued | 354,000 | $65,490 |
Director remuneration. As per announcement on 29-11-2024
|
| 26 Nov 2024 | Elizabeth Stoner | Issued | 354,000 | $65,490 |
Director remuneration.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Gary Phillips | Non-Executive Director | Jul 2022 |
Mr Phillips has more than 40 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia.
|
| Dr Thomas (Tom) Duthy | Non-Executive ChairmanNon-Executive Director | Mar 2023 |
Dr Duthy has over 20 years of direct financial markets experience and is the Founder and CEO of Nemean Group Pty Ltd, a boutique corporate advisory and investor relations firm specialising in the life sciences and technology sectors.
|
| Dr Michael Baker | Chief Executive OfficerManaging Director | Jan 2020 |
Dr Baker has over 15 years of experience in scientific research, drug development and venture investing. He was an Investment Manager with leading Australian life science fund, BioScience Managers, responsible for deal sourcing from networks, conferences, universities, and research institutes.
|
| Dr Debora Barton | Non-Executive Director | Aug 2021 |
Dr Barton has over 20 years of oncology experience, which includes 9 years of clinical management of oncology patients and enrolling patients in clinical trials in academia. In the pharmaceutical industry, she has experience in medical affairs and clinical development in both large pharmaceutical and small biotech companies, including regulatory interactions in the USA, Europe, Australia, and several countries around the world.
|
| Dr Elizabeth Stoner | Non-Executive Director | Nov 2021 |
Dr Stoner has over 30 years of experience in the life-science sector. She is currently an executive partner at MPM Capital, a leading US healthcare investment firm. In her role, Dr Stoner serves as a clinical advisor to several of MPM Capital's portfolio companies, including Antiva, and Rhythm Pharmaceuticals.
|
| Mr Tim Luscombe | Chief Financial OfficerCompany Secretary | Dec 2023 |
-
|
| Tim Luscombe | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| The Trust Company (Australia) Limited Mbf A/C | 59,019,000 | 5.62% |
| MB Investment Capital Pty Ltd | 27,749,415 | 2.64% |
| UBS Nominees Pty Ltd | 25,620,196 | 2.44% |
| Mr James Evan Hughes-Morris | 21,917,196 | 2.09% |
| Blackburne Capital Pty Ltd Blackburne Capital A/C | 20,695,706 | 1.97% |
| Mann Beef Pty Ltd | 20,000,000 | 1.90% |
| Mann Beef Pty Ltd i | 19,555,555 | 1.86% |
| DP Investment Capital Pty Ltd | 18,000,000 | 1.71% |
| Dylide Pty Ltd | 17,166,666 | 1.63% |
| TK Cooper Holdings Pty Ltd | 15,186,620 | 1.45% |
| M & M Stock One Pty Ltd The M & M Stock One A/C | 13,596,581 | 1.29% |
| Mr Neil Donald Delroy The Ndd Investment A/C | 13,067,222 | 1.24% |
| Ajava Holdings Pty Ltd | 12,543,194 | 1.19% |
| Murray James Way Pty Ltd | 12,022,400 | 1.14% |
| Mann Beef Pty Ltd Lochwall Super Fund A/C | 11,350,102 | 1.08% |
| Mrs Naomi Hughes Morris | 11,309,868 | 1.08% |
| Moovnup Pty Ltd Moovnup A/C | 11,067,962 | 1.05% |
| Widerange Corporation Pty Ltd | 10,390,789 | 0.99% |
| Mr Richard John Mann | 10,000,000 | 0.95% |
| Mr Brendan John Martin & Mrs Sharon Ann Martin Jaknic Super A/C | 9,564,970 | 0.91% |